Market capitalization | CHF4.36b |
Enterprise Value | CHF4.18b |
P/E (TTM) P/E ratio | 38.35 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.24 |
P/S ratio (TTM) P/S ratio | 7.54 |
P/B ratio (TTM) P/B ratio | 3.33 |
Dividend yield | 1.38% |
Last dividend (FY23) | CHF0.80 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Bachem Holding forecast:
8 Analysts have issued a Bachem Holding forecast:
Jun '24 |
+/-
%
|
||
Revenue | 578 578 |
8%
8%
|
|
Gross Profit | 179 179 |
13%
13%
|
|
EBITDA | 169 169 |
16%
16%
|
EBIT (Operating Income) EBIT | 129 129 |
18%
18%
|
Net Profit | 114 114 |
15%
15%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bachem Holding AG engages in the provision of peptides and oligonucleotides. It operates through the Europe/Asia and North America geographical segments. It offers project management, research grade production, catalog peptides, peptide NCES, and commercial NCES. The company was founded in 2003 and is headquartered in Bubendorf, Switzerland.
Head office | Switzerland |
CEO | Thomas Meier |
Employees | 2,006 |
Founded | 2003 |
Website | www.bachem.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.